Trial · NCT01691313

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT01691313, Phase 2, Completed, Laguna Pharmaceuticals, Inc.; results first posted 2015-12-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm. Trials, record NCT01691313. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01691313

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm
NCT number: NCT01691313
Status: Completed
Phases: Phase 2
Enrollment: 104 participants, actual
Lead sponsor: Laguna Pharmaceuticals, Inc.
Conditions: Symptomatic Atrial Fibrillation, Atrial Flutter
Interventions: Vanoxerine, Placebo
First posted: 2012-09-24
Last updated: 2015-12-22
Results first posted: 2015-12-22

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Conversion to Sinus Rhythm	baseline through 4 hours	proportion of subjects who convert to sinus rhythm through 4 hours after start of study drug
Primary	Conversion to Sinus Rhythm	baseline through 24 hours	proportion of subjects who convert to sinus rhythm through 24 hours after start of study drug

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Conversion to Sinus Rhythm	baseline through 4 hours		participants	NUMBER
PRIMARY	Conversion to Sinus Rhythm	baseline through 24 hours		participants	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Conversion to Sinus Rhythm	Placebo	4	participants
Conversion to Sinus Rhythm	Vanoxerine 200mg	4	participants
Conversion to Sinus Rhythm	Vanoxerine 300mg	11	participants
Conversion to Sinus Rhythm	Vanoxerine 400mg	13	participants
Conversion to Sinus Rhythm	Placebo	10	participants
Conversion to Sinus Rhythm	Vanoxerine 200mg	13	participants
Conversion to Sinus Rhythm	Vanoxerine 300mg	16	participants
Conversion to Sinus Rhythm	Vanoxerine 400mg	21	participants

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vanoxerine 200mg	22
Overall Study	STARTED	Placebo	32
Overall Study	STARTED	Vanoxerine 300mg	25
Overall Study	STARTED	Vanoxerine 400mg	25
Overall Study	COMPLETED	Vanoxerine 200mg	22
Overall Study	COMPLETED	Placebo	32
Overall Study	COMPLETED	Vanoxerine 300mg	25
Overall Study	COMPLETED	Vanoxerine 400mg	25
Overall Study	NOT COMPLETED	Vanoxerine 200mg	0
Overall Study	NOT COMPLETED	Placebo	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events108

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Sinus bradycardia	Cardiac disorders	Placebo	0	32	0
other	Sinus bradycardia	Cardiac disorders	Vanoxerine 200mg	0	22	0
other	Sinus bradycardia	Cardiac disorders	Vanoxerine 300mg	1	25	1
other	Sinus bradycardia	Cardiac disorders	Vanoxerine 400mg	2	25	2
other	Supraventricular extrasystoles	Cardiac disorders	Placebo	0	32	0
other	Supraventricular extrasystoles	Cardiac disorders	Vanoxerine 200mg	0	22	0
other	Supraventricular extrasystoles	Cardiac disorders	Vanoxerine 300mg	1	25	1
other	Supraventricular extrasystoles	Cardiac disorders	Vanoxerine 400mg	2	25	2
other	Ventricular extrasystoles	Cardiac disorders	Placebo	1	32	1
other	Ventricular extrasystoles	Cardiac disorders	Vanoxerine 200mg	0	22	0

1 to 10 of 108Source ClinicalTrials.gov

See all 108 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Vanoxerine 200mg
Total, all-cause mortality	Vanoxerine 300mg
Total, all-cause mortality	Vanoxerine 400mg
Total, other adverse events	Placebo	3	32
Total, other adverse events	Vanoxerine 200mg	3	22
Total, other adverse events	Vanoxerine 300mg	8	25
Total, other adverse events	Vanoxerine 400mg	17	25
Total, serious adverse events	Placebo	0	32
Total, serious adverse events	Vanoxerine 200mg	1	22

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25684233	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01691313

GET https://conductscience.org/api/trials/v1/NCT01691313/events?page=2

API reference For AI assistants